Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 157 articles:
HTML format
Text format



Single Articles


    April 2017
  1. BRECCIA M, Pregno P, Spallarossa P, Arboscello E, et al
    Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.
    Ann Hematol. 2017;96:549-558.
    PubMed     Text format     Abstract available


    March 2017
  2. BOTH A, Krauter J, Damm F, Thol F, et al
    The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
    Ann Hematol. 2017 Mar 22. doi: 10.1007/s00277-017-2967.
    PubMed     Text format     Abstract available


  3. MO XD, Zhang XH, Xu LP, Wang Y, et al
    Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2017 Mar 11. doi: 10.1007/s00277-017-2960.
    PubMed     Text format     Abstract available


  4. PAUBELLE E, Ducastelle-Lepretre S, Labussiere-Wallet H, Nicolini FE, et al
    Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
    Ann Hematol. 2017;96:363-371.
    PubMed     Text format     Abstract available


  5. HOLTICK U, Herling M, Pflug N, Chakupurakal G, et al
    Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
    Ann Hematol. 2017;96:479-487.
    PubMed     Text format     Abstract available


  6. GORNICEC M, Wolfler A, Stanzel S, Sill H, et al
    Evidence for a role of decitabine in the treatment of myeloid sarcoma.
    Ann Hematol. 2017;96:505-506.
    PubMed     Text format    


  7. THULER LC, Pombo-de-Oliveira MS
    Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012.
    Ann Hematol. 2017;96:355-362.
    PubMed     Text format     Abstract available


    February 2017
  8. GAO N, Wang XX, Sun JR, Yu WZ, et al
    Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
    Ann Hematol. 2017 Feb 25. doi: 10.1007/s00277-017-2948.
    PubMed     Text format     Abstract available


  9. JUD S, Goede JS, Senn O, Spanaus K, et al
    sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-alpha therapy.
    Ann Hematol. 2017 Feb 18. doi: 10.1007/s00277-017-2943.
    PubMed     Text format     Abstract available


  10. ZHANG X, Pan J
    Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
    Ann Hematol. 2017 Feb 2. doi: 10.1007/s00277-017-2923.
    PubMed     Text format    


  11. ORIOLI L, Sarti K, Van Den Neste E, Maiter D, et al
    Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia.
    Ann Hematol. 2017 Feb 1. doi: 10.1007/s00277-017-2928.
    PubMed     Text format    


  12. ITO S, Fujiwara SI, Mashima K, Umino K, et al
    Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
    Ann Hematol. 2017 Feb 1. doi: 10.1007/s00277-017-2933.
    PubMed     Text format     Abstract available



  13. ACUTE LEUKEMIAS XVI.
    Ann Hematol. 2017;96.
    PubMed     Text format    


    January 2017
  14. TALAMO L, Douvas M, Macik BG, Ornan D, et al
    Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management.
    Ann Hematol. 2017 Jan 28. doi: 10.1007/s00277-017-2930.
    PubMed     Text format    


  15. YOO SH, Koh Y, Kim DY, Lee JH, et al
    Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience.
    Ann Hematol. 2017 Jan 16. doi: 10.1007/s00277-017-2919.
    PubMed     Text format     Abstract available


  16. KONUMA T, Kondo T, Yamashita T, Uchida N, et al
    Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.
    Ann Hematol. 2017 Jan 6. doi: 10.1007/s00277-016-2909.
    PubMed     Text format     Abstract available


  17. HILLER JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, et al
    Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
    Ann Hematol. 2017 Jan 5. doi: 10.1007/s00277-016-2912.
    PubMed     Text format     Abstract available


  18. RAM R, Gatt M, Merkel D, Helman I, et al
    Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study.
    Ann Hematol. 2017 Jan 5. doi: 10.1007/s00277-016-2914.
    PubMed     Text format     Abstract available


  19. LIU J, Qin YZ, Yang S, Wang Y, et al
    Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.
    Ann Hematol. 2017 Jan 4. doi: 10.1007/s00277-016-2913.
    PubMed     Text format     Abstract available


  20. LEE JS, Cheong HS, Koh Y, Ahn KS, et al
    MCM7 polymorphisms associated with the AML relapse and overall survival.
    Ann Hematol. 2017;96:93-98.
    PubMed     Text format     Abstract available


  21. MANGIACAVALLI S, Pompa A, Ferretti V, Klersy C, et al
    The possible role of burden of therapy on the risk of myeloma extramedullary spread.
    Ann Hematol. 2017;96:73-80.
    PubMed     Text format     Abstract available


  22. PIREDDA ML, Catalano G, Ciardi C, Divona M, et al
    Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.
    Ann Hematol. 2017;96:155-157.
    PubMed     Text format    


  23. FILIP AA, Grenda A, Popek S, Koczkodaj D, et al
    Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
    Ann Hematol. 2017;96:33-50.
    PubMed     Text format     Abstract available


  24. ZDRENGHEA M, Bagacean C, Renaudineau Y, Salaun PY, et al
    Isolated Cardiac Richter Syndrome: a Case Report.
    Ann Hematol. 2017;96:147-149.
    PubMed     Text format    


    December 2016
  25. GONG Z, Zheng L, Tang Z, Chen Z, et al
    Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Ann Hematol. 2016.
    PubMed     Text format    


  26. KOURIE HR, Ameye L, Paesmans M, Bron D, et al
    Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
    Ann Hematol. 2016;95:2105-2106.
    PubMed     Text format    


  27. CATTANEO C, Zappasodi P, Mancini V, Annaloro C, et al
    Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).
    Ann Hematol. 2016;95:1955-1963.
    PubMed     Text format     Abstract available


  28. HAERZSCHEL A, Catusse J, Hutterer E, Paunovic M, et al
    BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.
    Ann Hematol. 2016;95:1979-1988.
    PubMed     Text format     Abstract available


    November 2016
  29. HEIBLIG M, Bidet A, Callet-Bauchu E, Dumas PY, et al
    Erratum to: BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
    Ann Hematol. 2016.
    PubMed     Text format    


  30. YU CL, Zheng-Dong, Qiao ZH, Wang JM, et al
    The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  31. YAMASAKI S, Hirakawa A, Aoki J, Uchida N, et al
    Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  32. ZHANG W, Kuang P, Li H, Wang F, et al
    Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  33. ZHENG C, Tang B, Zhu X, Zhang X, et al
    Pre-engraftment bloodstream infections in acute leukemia patients undergoing unrelated cord blood transplantation following intensified myeloablative conditioning without ATG.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  34. HIROSAWA M, Higashi T, Iwashige A, Yamaguchi T, et al
    HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.
    Ann Hematol. 2016.
    PubMed     Text format    


  35. MAEL H, Audrey B, Evelyne CB, Pierre-Yves D, et al
    BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
    Ann Hematol. 2016.
    PubMed     Text format    


  36. BRIANI C, Visentin A, Cavallaro T, Cacciavillani M, et al
    Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  37. CERVANTES F, Correa JG, Perez I, Garcia-Gutierrez V, et al
    Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  38. BOZTUG H, Muhlegger N, Potschger U, Attarbaschi A, et al
    Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  39. DIAMOND JM, de Almeida AM, Belo HJ, da Costa MP, et al
    CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.
    Ann Hematol. 2016.
    PubMed     Text format    


  40. VOGT N, Hess K, Bialek R, Buerke B, et al
    Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  41. SCHLENK RF, Lubbert M, Benner A, Lamparter A, et al
    All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  42. DAI Z, Feng C, Zhang W, Liu J, et al
    Lack of association between cytotoxic T-lymphocyte antigen-4 gene polymorphisms and lymphoid malignancy risk: evidence from a meta-analysis.
    Ann Hematol. 2016;95:1685-94.
    PubMed     Text format     Abstract available


  43. CRISP RL, Maltaneri RE, Vittori DC, Solari L, et al
    Red blood cell aquaporin-1 expression is decreased in hereditary spherocytosis.
    Ann Hematol. 2016;95:1595-601.
    PubMed     Text format     Abstract available


  44. WU SJ, Lin CT, Lin SC, Hsieh PY, et al
    Similar epidemiological trends of pre-neoplastic precursors and their respective lymphoid malignancies in Taiwan.
    Ann Hematol. 2016;95:1727-9.
    PubMed     Text format    


  45. MLIKA M, Khanfir D, Mansouri R, El Mezni F, et al
    Multivariate analysis of prognostic factors of lymphoblastic lymphomas of the mediastinum.
    Ann Hematol. 2016;95:1731-2.
    PubMed     Text format    


  46. PARK H, Youk J, Kim I, Yoon SS, et al
    Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Ann Hematol. 2016;95:1777-86.
    PubMed     Text format     Abstract available


  47. CHRISTOPEIT M, Grundhoff A, Rohde H, Belmar-Campos C, et al
    Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing.
    Ann Hematol. 2016;95:1919-21.
    PubMed     Text format    


    September 2016
  48. JUNCA J, Garcia O, Garcia-Caro M, Vila J, et al
    CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  49. PEI YQ, Wu Y, Wang F, Cui W, et al
    Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
    Ann Hematol. 2016;95:1391-8.
    PubMed     Text format     Abstract available


  50. FISCHER J, Hamacher L, Fries J, Hallek M, et al
    Rhodotorula mucilaginosa as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL.
    Ann Hematol. 2016;95:1569-70.
    PubMed     Text format    


  51. BURBACH M, Birsen R, Denis B, Munier AL, et al
    A case of BK virus nephropathy without hemorrhagic cystitis after hematopoietic stem cell transplantation.
    Ann Hematol. 2016;95:1567-8.
    PubMed     Text format    


    August 2016
  52. LOW MS, Vilcassim S, Fedele P, Grigoriadis G, et al
    Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions.
    Ann Hematol. 2016.
    PubMed     Text format    


  53. REISS SN, Buie LW, Adel N, Goldman DA, et al
    Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  54. REFAEI M, Fernandes B, Brandwein J, Goodyear MD, et al
    Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  55. MORRISON EJ, Flynn JM, Jones J, Byrd JC, et al
    Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  56. LIU X, Liu S, Chen J, He L, et al
    Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt/beta-catenin signaling.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  57. GOPEL W, Schnetzke U, Hochhaus A, Scholl S, et al
    Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
    Ann Hematol. 2016.
    PubMed     Text format    


  58. HIRABAYASHI S, Kondo T, Oka T, Akamatsu Y, et al
    Successful treatment of severe acute gastrointestinal graft-versus-host disease complicated by cytomegalovirus gastroenteritis with intra-arterial steroid infusion.
    Ann Hematol. 2016;95:1373-5.
    PubMed     Text format    


    July 2016
  59. KONISHI Y, Tada K, Nishi K, Imada K, et al
    Allogeneic bone marrow transplantation for therapy-related acute lymphocytic leukemia after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Ann Hematol. 2016.
    PubMed     Text format    


  60. KIM TK, Xu ML, Podoltsev NA, Prebet T, et al
    Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  61. PETERLIN P, Garnier A, Tissot A, Garandeau C, et al
    Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.
    Ann Hematol. 2016.
    PubMed     Text format    


  62. VISWESHWAR N, Jaglal M, Booth C, Griffin P, et al
    AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  63. BURKHARDT B, Yavuz D, Zimmermann M, Schieferstein J, et al
    Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  64. FAYE BF, Dieng N, Seck M, Gadji M, et al
    Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  65. LIANG L, Zhao M, Zhu YC, Hu X, et al
    Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  66. NEUENDORFF NR, Burmeister T, Dorken B, Westermann J, et al
    BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  67. MOLLOY C, Cahill R, Gallagher D, Murphy P, et al
    Early-onset chronic lymphocytic leukaemia in a young man with Cowden syndrome.
    Ann Hematol. 2016;95:1205-6.
    PubMed     Text format    


  68. WU W, Lin Y, Xiang L, Dong W, et al
    Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
    Ann Hematol. 2016;95:1051-7.
    PubMed     Text format     Abstract available


    May 2016
  69. WU B, Ingersoll K, Rehder C, Sebastian S, et al
    Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclon
    Ann Hematol. 2016.
    PubMed     Text format    


  70. BYUN JM, Kim YJ, Yoon HJ, Kim SY, et al
    Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  71. BARTELS S, Lehmann U, Busche G, Schlue J, et al
    Evolution of chronic myelomonocytic leukemia to myeloproliferative neoplasm.
    Ann Hematol. 2016.
    PubMed     Text format    


  72. SEYMOUR JF
    Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  73. SOUTO FILHO JT, Pereira SM, Duncan LR, Alves LL, et al
    Resolution of organizing pneumonia following immunosuppressive therapy for large granular lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  74. CARLI G, Visco C, Falisi E, Perbellini O, et al
    Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome.
    Ann Hematol. 2016;95:863-70.
    PubMed     Text format     Abstract available


  75. ERNST J, Schafer V, Rinke J, Wittig S, et al
    Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
    Ann Hematol. 2016;95:1027-30.
    PubMed     Text format    


    April 2016
  76. SANZ MA, Iacoboni G, Montesinos P, Venditti A, et al
    Emerging strategies for the treatment of older patients with acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  77. AWAN FT, Jones JA, Maddocks K, Poi M, et al
    A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  78. GHANIZADEH-VESALI S, Zekri A, Zaker F, Zaghal A, et al
    Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  79. STAHL M, Xu ML, Steensma DP, Rampal R, et al
    Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  80. LINDNER S, Berg T, Riemann J, Ajib S, et al
    Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  81. CESARO S, Cavaliere M, Pegoraro A, Gamba P, et al
    A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients.
    Ann Hematol. 2016;95:817-25.
    PubMed     Text format     Abstract available


  82. APPELMANN I, Kreher S, Parmentier S, Wolf HH, et al
    Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thromb
    Ann Hematol. 2016;95:707-18.
    PubMed     Text format     Abstract available


  83. MALAGOLA M, Papayannidis C, Baccarani M
    Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
    Ann Hematol. 2016;95:681-93.
    PubMed     Text format     Abstract available


  84. HUANG K, Yang M, Pan Z, Heidel FH, et al
    Leukemogenic potency of the novel FLT3-N676K mutant.
    Ann Hematol. 2016;95:783-91.
    PubMed     Text format     Abstract available


    March 2016
  85. ZOELLNER AK, Hohler T, Fries S, Bohme A, et al
    Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  86. GRATWOHL A, Iacobelli S, Bootsman N, van Biezen A, et al
    Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  87. BENETATOS L, Vartholomatos G
    On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  88. KJELLANDER C, Bjorkholm M, Kallman O, Giske CG, et al
    Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  89. MONABATI A, Safaei A, Noori S, Mokhtari M, et al
    Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification.
    Ann Hematol. 2016;95:613-8.
    PubMed     Text format     Abstract available


  90. AHN JS, Kim HJ, Kim YK, Jung SH, et al
    Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ann Hematol. 2016;95:625-35.
    PubMed     Text format     Abstract available


    February 2016
  91. URESHINO H, Miyahara M
    Spontaneous regression of adult T cell leukemia/lymphoma following development of immune thrombocytopenia.
    Ann Hematol. 2016.
    PubMed     Text format    


  92. TESTA U, Lo-Coco F
    Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  93. PICH A, Godio L, Riera L, Cavaliere C, et al
    Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.
    Ann Hematol. 2016;95:525-7.
    PubMed     Text format    


    January 2016
  94. MENON NN, Jenkins LM, Cui H, Jenkins C, et al
    Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  95. WANG W, Ali S, Tang Z, Miranda RN, et al
    Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  96. TANBA K, Uoshima N, Uchiyama H, Kawata E, et al
    Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab.
    Ann Hematol. 2016.
    PubMed     Text format    


  97. KUBOTA Y, Ichinohe T, Yoshimura M, Itamura H, et al
    Acute myeloid leukemia with t(3;8)(q26;q24) complicated by diabetes insipidus.
    Ann Hematol. 2016.
    PubMed     Text format    


  98. SCHNEIDAWIND D, Federmann B, Buechele C, Helwig A, et al
    Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.
    Ann Hematol. 2016;95:115-24.
    PubMed     Text format     Abstract available


  99. HEIDENREICH D, Kreil S, Nolte F, Reinwald M, et al
    Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis.
    Ann Hematol. 2016;95:287-93.
    PubMed     Text format     Abstract available


  100. LUQUE PAZ D, Ianotto JC, Chauveau A, Guibourg B, et al
    Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
    Ann Hematol. 2016;95:349-50.
    PubMed     Text format    


    December 2015
  101. PODHORECKA M, Macheta A, Chocholska S, Bojarska-Junak A, et al
    Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  102. LIU AP, Lee V, Li CK, Ha SY, et al
    Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  103. AHN JS, Kim JY, Kim HJ, Kim YK, et al
    Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ann Hematol. 2015.
    PubMed     Text format    


  104. FABARIUS A, Kalmanti L, Dietz CT, Lauseker M, et al
    Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
    Ann Hematol. 2015;94:2015-24.
    PubMed     Text format     Abstract available


  105. FASAN A, Haferlach C, Eder C, Alpermann T, et al
    Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML.
    Ann Hematol. 2015;94:1991-2001.
    PubMed     Text format     Abstract available


    November 2015
  106. LUBBERT M, Suciu S, Hagemeijer A, Ruter B, et al
    Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  107. EFFICACE F, Rosti G, Breccia M, Cottone F, et al
    The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  108. AHN JS, Kim JY, Kim HJ, Kim YK, et al
    Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  109. TSCHAN-PLESSL A, Halter JP, Heim D, Medinger M, et al
    Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
    Ann Hematol. 2015;94:1899-905.
    PubMed     Text format     Abstract available


  110. PIEKARSKA A, Gil L, Prejzner W, Wisniewski P, et al
    Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.
    Ann Hematol. 2015;94:1891-7.
    PubMed     Text format     Abstract available


    October 2015
  111. NIAVARANI A, Horswell S, Sadri R, Bonnet D, et al
    The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  112. MORI J, Ishiyama K, Yamaguchi T, Tanaka J, et al
    Outcomes of allogeneic hematopoietic cell transplantation in patients with biphenotypic acute leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  113. SIMON P, Suciu S, Clappier E, Cave H, et al
    Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  114. RASHIDI A, Conkling PR, Fisher SI
    Acute promyelocytic leukemia following solid organ transplantation.
    Ann Hematol. 2015.
    PubMed     Text format    


  115. BOHN JP, Willenbacher E, Steurer M
    Obinutuzumab in multidrug-resistant hairy cell leukemia.
    Ann Hematol. 2015.
    PubMed     Text format    


  116. CHAKUPURAKAL G, Leitzke S, Langerbeins P, Schiller J, et al
    Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.
    Ann Hematol. 2015;94:1717-25.
    PubMed     Text format     Abstract available


    September 2015
  117. DE WITTE T, Suciu S, Meert L, Halkes C, et al
    Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  118. BECKER H, Suciu S, Ruter BH, Platzbecker U, et al
    Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MD
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  119. KAKO S, Akahoshi Y, Harada N, Nakano H, et al
    Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  120. KORDELAS L, Gromke T, Trenschel R, Ditschkowski M, et al
    CD34+ highly enriched allogeneic stem cell transplantation in a patient with mixed phenotype acute leukemia and Fusarium solani sepsis.
    Ann Hematol. 2015.
    PubMed     Text format    


  121. ZHENG R, Xie B, Wang C, Yu B, et al
    D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
    Ann Hematol. 2015.
    PubMed     Text format    


  122. YUAN L, Lu L, Yang Y, Sun H, et al
    Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  123. ST BERNARD R, Hsia CC
    Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia.
    Ann Hematol. 2015.
    PubMed     Text format    


  124. SANDHERR M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, et al
    Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).
    Ann Hematol. 2015;94:1441-50.
    PubMed     Text format     Abstract available


    August 2015
  125. LOU Y, Ma Y, Sun J, Ye X, et al
    Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  126. SCHRENK KG, Katenkamp K, Felber J, Mugge LO, et al
    Lower gastrointestinal bleeding in a patient with Crohn's disease and plasma cell leukemia in remission.
    Ann Hematol. 2015.
    PubMed     Text format    


  127. SEGOT A, Raffoux E, Lengline E, Thieblemont C, et al
    Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  128. WONG GC
    Hyperleukocytosis in acute myeloid leukemia patients is associated with high 30-day mortality which is not improved with leukapheresis.
    Ann Hematol. 2015.
    PubMed     Text format    


  129. SHI M, Spurgeon S, Press R, Olson S, et al
    MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting.
    Ann Hematol. 2015.
    PubMed     Text format    


  130. SANZ MA, Montesinos P, Kim HT, Ruiz-Arguelles GJ, et al
    All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
    Ann Hematol. 2015;94:1347-56.
    PubMed     Text format     Abstract available


    July 2015
  131. BIGLIARDI S, Morselli M, Potenza L, Riva G, et al
    Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study
    Ann Hematol. 2015.
    PubMed     Text format    


  132. GEIGER O, Hatzl S, Kashofer K, Hoefler G, et al
    Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia.
    Ann Hematol. 2015.
    PubMed     Text format    


  133. CANNAS G, Fattoum J, Raba M, Dolange H, et al
    Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  134. XU Z, Padmore R, Shier L, Beaulieu Bergeron M, et al
    A rare case of acute leukemia of ambiguous lineage overexpressing C-MYC with monosomy 7 and Philadelphia chromosome.
    Ann Hematol. 2015.
    PubMed     Text format    


  135. BAE MH, Oh SH, Park CJ, Lee BR, et al
    VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  136. BOYER T, Grardel N, Copin MC, Roumier C, et al
    Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia-an unusual association: another cause of cytopenia in PNH.
    Ann Hematol. 2015.
    PubMed     Text format    


  137. BARTELS S, Lehmann U, Busche G, Schlue J, et al
    De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
    Ann Hematol. 2015;94:1255-6.
    PubMed     Text format    


  138. CHEUNG CY, Ip AH, Iu PL, Lee EY, et al
    Retinal and central nervous system involvement in T cell large granular lymphocyte leukaemia.
    Ann Hematol. 2015;94:1245-6.
    PubMed     Text format    


  139. YAMASAKI S, Yoshimoto G, Ogawa R, Aoki K, et al
    Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
    Ann Hematol. 2015;94:1159-65.
    PubMed     Text format     Abstract available


    June 2015
  140. TIAN C, Yu Y, Jia Y, Zhu L, et al
    HES1 activation suppresses proliferation of leukemia cells in acute myeloid leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  141. NISCOLA P, Siniscalchi A, Tendas A, Scaramucci L, et al
    Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders.
    Ann Hematol. 2015.
    PubMed     Text format    


  142. LUCIJANIC M, Lasan-Trcic R, Kusec R, Pejsa V, et al
    Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.
    Ann Hematol. 2015.
    PubMed     Text format    


  143. IMANISHI S, Takahashi R, Ohsuga M, Ohyashiki K, et al
    Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro.
    Ann Hematol. 2015.
    PubMed     Text format    


  144. COUGOUL P, Tournier E, Delavigne K, Rauzy OB, et al
    Acquired epidermodysplasia verruciformis, a new opportunistic infection related to bendamustine.
    Ann Hematol. 2015;94:1071-3.
    PubMed     Text format    


  145. MESSORI A, Fadda V, Maratea D, Trippoli S, et al
    First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis.
    Ann Hematol. 2015;94:1003-9.
    PubMed     Text format     Abstract available


  146. LAUSEKER M, Hasford J, Hoffmann VS, Muller MC, et al
    A multi-state model approach for prediction in chronic myeloid leukaemia.
    Ann Hematol. 2015;94:919-27.
    PubMed     Text format     Abstract available


    May 2015
  147. SCHNEIDER T, Florcken A, Singh A, Turkmen S, et al
    Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  148. SHAH U, Kritharis A, Evens AM
    Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder.
    Ann Hematol. 2015;94:893-4.
    PubMed     Text format    


  149. HWANG SY, Kim MS, Yoo NJ, Lee SH, et al
    Mutational analysis of oncogenic CSF3R p.T618I in acute leukemias and common solid cancers.
    Ann Hematol. 2015;94:889-90.
    PubMed     Text format    


    April 2015
  150. HOGLUND M, Sandin F, Simonsson B
    Epidemiology of chronic myeloid leukaemia: an update.
    Ann Hematol. 2015;94 Suppl 2:S241-7.
    PubMed     Text format     Abstract available


  151. HANFSTEIN B, Muller MC, Hochhaus A
    Response-related predictors of survival in CML.
    Ann Hematol. 2015;94 Suppl 2:S227-39.
    PubMed     Text format     Abstract available


  152. TALPAZ M, Mercer J, Hehlmann R
    The interferon-alpha revival in CML.
    Ann Hematol. 2015;94 Suppl 2:S195-207.
    PubMed     Text format     Abstract available


  153. MAHON FX
    Discontinuation of tyrosine kinase therapy in CML.
    Ann Hematol. 2015;94 Suppl 2:S187-93.
    PubMed     Text format     Abstract available


  154. PALANI R, Milojkovic D, Apperley JF
    Managing pregnancy in chronic myeloid leukaemia.
    Ann Hematol. 2015;94 Suppl 2:S167-76.
    PubMed     Text format     Abstract available


  155. BACCARANI M, Castagnetti F, Gugliotta G, Rosti G, et al
    A review of the European LeukemiaNet recommendations for the management of CML.
    Ann Hematol. 2015;94 Suppl 2:S141-7.
    PubMed     Text format     Abstract available


  156. CHEREDA B, Melo JV
    Natural course and biology of CML.
    Ann Hematol. 2015;94 Suppl 2:S107-21.
    PubMed     Text format     Abstract available


  157. HEHLMANN R
    CML--Where do we stand in 2015?
    Ann Hematol. 2015;94 Suppl 2:S103-5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: